4//SEC Filing
Dolan Matthew Vincent 4
Accession 0001093557-22-000155
CIK 0001093557other
Filed
Sep 5, 8:00 PM ET
Accepted
Sep 6, 9:33 AM ET
Size
5.0 KB
Accession
0001093557-22-000155
Insider Transaction Report
Form 4
DEXCOM INCDXCM
Dolan Matthew Vincent
EVP, Strategy & Corporate Dev
Transactions
- Sale
Common Stock
2022-09-01$81.63/sh−5$408→ 26,536 total
Footnotes (2)
- [F1]On December 15, 2021, Mr. Dolan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan.
- [F2]Adjusted to reflect Dexcom's 4-for-1 stock split, effective on June 10, 2022. Included in this number are 26,536 unvested restricted stock units, 11,556 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,192 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 6,788 of which were granted on March 8, 2020 and shall vest through March 8, 2023.
Documents
Issuer
DEXCOM INC
CIK 0001093557
Entity typeother
Related Parties
1- filerCIK 0001914994
Filing Metadata
- Form type
- 4
- Filed
- Sep 5, 8:00 PM ET
- Accepted
- Sep 6, 9:33 AM ET
- Size
- 5.0 KB